The Innova Captab IPO date has been confirmed from December 21, 2023 and closes on December 26, 2023.
Using an IPO, Innova Captab is seeking to raise Rs 570.00 crores. Its price band is set at ₹426 to ₹448 per share. The minimum lot size for an application is 33 Shares. The minimum amount of investment required by retail investors is ₹14,784. The minimum lot size investment for sNII is 14 lots (462 shares), amounting to ₹206,976, and for bNII, it is 68 lots (2,244 shares), amounting to ₹1,005,312.
Start your investing journey today. How do you open your own demat account for free?
Bidding Dates
December 21-26
Price Range
₹426 to ₹448 per share
Face Value
INR 10 per share
GMP
₹32
Innova Captab IPO GMP
The Innova Captab Limited IPO GMP is ₹32.
IPO Overview
The Innova Captab IPO is a Rs 570.00 crore book-built issuance. The offering consists of a fresh issue of Rs 320.00 crore and an offer to sell 0.56 crore shares. The Innova Captab IPO goes on sale on December 21, 2023, and closes on December 26, 2023. The Innova Captab IPO allotment is expected to be completed on Wednesday, December 27, 2023. The Innova Captab IPO will be listed on the BSE and NSE, with a tentative listing date of Friday, December 29, 2023.
Cipla Limited, Glenmark Pharmaceuticals Limited, Wockhardt Limited, Corona Remedies Private Limited, Emcure Pharmaceuticals Limited, Lupin Limited, Intas Pharmaceuticals Limited, Leeford Healthcare Limited, Medley Pharmaceuticals Limited, Cachet Pharmaceuticals Limited, Eris Healthcare Private Limited, Indoco Remedies Limited, J. B. Chemicals and Pharmaceuticals Limited, Oaknet Healthcare Private Limited, Zuventus Healthcare Limited are among the company’s customers. As of October 31, 2023, the company had 200 current product registrations and 20 registrations seeking renewal with international agencies. In addition, 218 additional registration applications are being processed with international agencies.
Innova Captab IPO Details
| IPO Date | December 21, 2023 to December 26, 2023 |
| Listing Date | [.] |
| Face Value | ₹10 per share |
| Price Band | ₹426 to ₹448 per share |
| Lot Size | 33 Shares |
| Total Issue Size | [.] shares (aggregating up to ₹570.00 Cr) |
| Fresh Issue | [.] shares (aggregating up to ₹320.00 Cr) |
| Offer for Sale | 5,580,357 shares of ₹10 (aggregating up to ₹250.00 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| Share holding pre issue | 50,082,072 |
Innova Captab Limited Financial Information
| Period Ended | 30 Jun 2023 | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
| Assets | 1,086.16 | 704.41 | 575.48 | 369.62 |
| Revenue | 234.37 | 935.58 | 803.41 | 412.03 |
| Profit After Tax | 17.59 | 67.95 | 63.95 | 34.50 |
| Net Worth | 294.27 | 276.46 | 208.56 | 144.78 |
| Reserves and Surplus | 228.51 | 67.90 | 196.61 | 132.82 |
| Total Borrowing | 441.90 | 235.19 | 198.18 | 45.03 |
Innova Captab IPO Timeline
| IPO Open Date | Thursday, December 21, 2023 |
| IPO Close Date | Tuesday, December 26, 2023 |
| Basis of Allotment | Wednesday, December 27, 2023 |
| Initiation of Refunds | Thursday, December 28, 2023 |
| Credit of Shares to Demat | Thursday, December 28, 2023 |
| Listing Date | Friday, December 29, 2023 |
| Cut-off time for UPI mandate confirmation | 5 PM on December 26, 2023 |
Company Profile
Innova Captab Limited, founded in January 2005, is a pharmaceutical firm with three business categories. For starters, it offers contract development and production services to Indian pharmaceutical firms. Second, the company operates a domestic business that sells branded generics. Finally, the corporation includes an overseas division that deals with branded generics. Tablets, capsules, dry syrups, dry powder injections, ointments, and liquid medicines are among the products offered by the organisation. The company produced and marketed about 600
distinct types of generics for the fiscal year 2023 and the three months ending June 30, 2023. These products were distributed in the Indian market under the company’s own brands by a network of around 5,000 distributors and stockists and over 150,000 retail pharmacies. Furthermore, Innova Capitab exported its branded generic products to 20 and 16 countries, respectively, in FY2023 and the three months ended June 30, 2023. The corporation employed 29 scientists and engineers in its research and development laboratory as of October 31, 2023. Buddi, Haryana, is where the company’s production facility is located.
Registrar Info
| Name | Kfin Technologies Limited |
| Phone number | 04067162222, 04079611000 |
| Email ID | innovacaptab.ipo@kfintech.com |
| Website | kosmic.kfintech.com |
Contact Details
| Name | Innova Captab Limited |
| Phone number | +91 22 2564 2095 |
| Email ID | investors@innovacaptab.com |
| Website | innovacaptab.com |
IPO Strenghts
- Experienced promoters and a competent management team.
- Well-established relationships with a loyal customer base.
- Access to markets worldwide, enabling global reach.
IPO Weakness
- Heavy reliance on customers based in the United States.
- Need to adhere to multiple laws and regulations in these countries to ensure compliance.
- Competition from other players in the market.
